Compare Moderna, Inc. (MRNA) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Northrop Grumman Corporation — how do they compare? Moderna, Inc. trades at $63.85 (market cap $24.18B), while Northrop Grumman Corporation trades at $577 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 3.4× Moderna, Inc.'s market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | NOC | |
|---|---|---|
Market Cap | $24.18B | $81.78B |
Sector | Health | Industrials |
52-Week High | $81.80 | $768.02 |
52-Week Low | $22.36 | $496.02 |
Enterprise Value | $20.33B | $95.77B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Northrop Grumman (NOC) trades at $577.12, down 0.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $7.68, and raised full-year guidance, supported by a record $105 billion backlog. Revenue growth is steady, with 2026 projected at $42.9 billion, and profitability remains solid with a net income margin of 10.48%.
The outlook is positive, driven by strategic contracts like the $7.6 billion Sentinel program and defense spending tailwinds. Risks include margin pressures from specific programs and geopolitical uncertainties. Analysts are bullish with a consensus price target of $598.57, suggesting upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
